Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 68 Carcinoma, Non-Small-Cell Lung 41 Carcinoma, Renal Cell 36 Neoplasm Metastasis 22 Carcinoma, Hepatocellular 15 Neoplasms 14 Colorectal Neoplasms 13 Brain Neoplasms 13 Skin Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 11 Pancreatic Neoplasms 10 Lung Neoplasms 10 Kidney Neoplasms 10 Uveal Melanoma 9 Ovarian Neoplasms 9 Urinary Bladder Neoplasms 8 Sarcoma 8 Prostatic Neoplasms 8 Carcinoma, Transitional Cell 8 Mesothelioma 7 Glioblastoma 7 Clear-cell metastatic renal cell carcinoma 7 Carcinoma, Merkel Cell 7 Recurrence 6 Colonic Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Myelodysplastic Syndromes 5 Multiple Myeloma 5 Mesothelioma, Malignant 5

Interventions

tremelimumab 1 evolocumab 1 durvalumab 1 Nivolumab 1 Ipilimumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Cancer Metastatic × Ipilimumab × 1 year × Clear all

NCT05144529 2026-05-05

TOP2101

Duke University

Phase 2 Terminated

19 enrolled 16 charts

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡